<DOC>
	<DOCNO>NCT00245050</DOCNO>
	<brief_summary>RATIONALE : Pyridoxine ( vitamin B6 ) may prevent lessen hand-foot syndrome cause chemotherapy . It yet know whether pyridoxine effective placebo prevent hand-foot syndrome . PURPOSE : This randomized clinical trial study pyridoxine see well work compare placebo prevent hand-foot syndrome patient receive liposomal doxorubicin recurrent ovarian , fallopian tube , peritoneal cancer , metastatic breast cancer , advance endometrial cancer .</brief_summary>
	<brief_title>Pyridoxine Preventing Hand-Foot Syndrome Patients Who Are Receiving Liposomal Doxorubicin Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy pyridoxine v placebo prevent palmar-plantar erythrodysesthesia ( PPE ) patient receive doxorubicin HCl liposome recurrent ovarian , fallopian tube , peritoneal cavity cancer , metastatic breast cancer , advance endometrial cancer . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind study . Patients stratify accord cancer type ( ovarian , fallopian tube , peritoneal cavity cancer v breast cancer vs endometrial cancer ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin HCl liposome IV 40mg/m2 1 hour day 1 oral pyridoxine 100 mg twice daily day 1-28 . - Arm II : Patients receive doxorubicin HCl liposome IV 40mg/m2 1 hour day 1 oral placebo 100 mg twice daily day 1-28 . In arm , treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients develop grade 2-3 palmar-plantar erythrodysesthesia despite dose reduction doxorubicin HCl liposome unblinded remove study ( patient arm I ) OR receive oral pyridoxine twice daily begin day 1 next plan therapy ( patient arm II ) . Quality life assess baseline every third course therapy . After completion study treatment , patient follow periodically 6 month . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Recurrent ovarian , fallopian tube , peritoneal cavity cancer Metastatic breast cancer Advanced endometrial cancer Planning receive chemotherapy doxorubicin HCl liposome dose 40 mg/m^2 Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Sex Not specify Menopausal status : Not specify Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic AST ALT ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN Bilirubin normal Renal Creatinine ≤ 2.0 mg/dL Cardiovascular Ejection fraction ≥ 50 % MUGA 2D echocardiogram No history cardiac disease No New York Heart Association class IIIV heart disease No clinical evidence congestive heart failure Other Not pregnant nursing Fertile patient must use effective contraception 3 month completion study treatment No active infection require antibiotic No history hypersensitivity reaction attribute conventional formulation doxorubicin HCl doxorubicin HCl liposome component No invasive malignancy within past 5 year except nonmelanoma basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 week since prior biologic immunologic agent cancer Chemotherapy Recovered prior chemotherapy Alopecia neuropathy allow No prior doxorubicin HCl liposome Other concurrent chemotherapy allow provide palmarplantar erythrodysesthesia one side effect therapy No concurrent cytarabine , fluorouracil , liposomal daunorubicin , capecitabine No concurrent premedication corticosteroid part chemotherapy regimen Endocrine therapy See Chemotherapy At least 3 week since prior concurrent oral topical corticosteroid At least 1 week since prior hormonal therapy cancer Concurrent hormone replacement therapy allow Radiotherapy At least 3 week since prior radiotherapy cancer recover Surgery Recovered prior surgery Other At least 3 week since prior concurrent form pyridoxine except include multivitamin No prior anticancer treatment contraindicate study treatment No concurrent amifostine protective agent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>